July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
AAV mediated delivery of NT4 specifically to Müller glial cells promotes retinal ganglion cell survival in the DBA/2J mouse model of glaucoma.
Author Affiliations & Notes
  • Anna M Demetriades
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Chendong Pan
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Leah Byrne
    Helen Wills Neuroscience Institute, Berkeley, California, United States
  • Jeffrey Harder
    The Jackson Laboratory, Bar Harbor, Maine, United States
  • Simon W John
    The Jackson Laboratory, Bar Harbor, Maine, United States
  • John Gerard Flannery
    Helen Wills Neuroscience Institute, Berkeley, California, United States
  • Footnotes
    Commercial Relationships   Anna Demetriades, None; Chendong Pan, None; Leah Byrne, None; Jeffrey Harder, None; Simon John, None; John Flannery, None
  • Footnotes
    Support  Research to Prevent Blindness; The New York Community Trust; BrightFocus Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 6135. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna M Demetriades, Chendong Pan, Leah Byrne, Jeffrey Harder, Simon W John, John Gerard Flannery; AAV mediated delivery of NT4 specifically to Müller glial cells promotes retinal ganglion cell survival in the DBA/2J mouse model of glaucoma.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):6135.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study examined the efficacy of using a cell-specific AAV vector (ShH10) to express Neurotophin-4 (NT4) in Müller glial cells as a method of promoting retinal ganglion cell survival in a long-term model of glaucoma.

Methods : 3-month old DBA/2J mice received either an intravitreal injection (1x1010 vector genomes) of ShH10.NT4, an ShH10.GFP control or no injection. Ocular examinations and eye pressure measurements were performed at bimonthly intervals. Mice were sacrificed at 10.5 months. NT4 ELISA assay was performed on ocular tissues and RGC survival was quantified.

Results : At 10.5 months, untreated eyes had significantly higher eye pressure (23.5±6.9, n=162) compared to ShH10.NT4 treated eyes (19.8±8, n=168, p=0.001) and Sh10.GFP eyes (18.3±8.5, n=168, p=0.008). ShH10.NT4 eyes had less iris transillumination defects compared to ShH10.GFP and untreated eyes. NT4 levels (pg/mg total protein) were increased in ShH10.NT4 eyes compared to ShH10.GFP eyes and untreated eyes in iris tissue (1904 vs. 29 and 25), retinal tissue (1627 vs. 178 and 437) and optic nerve (252 vs. undetectable and 122) (n=5). ShH10.NT4 eyes showed 2.6 times greater RGC density (1361 ± 51 cells/mm2, n=56) compared to untreated eyes (531 ± 39 cells/mm2, n=32, p<0.0001) and 2.3 times greater RGC density compared to ShH10.GFP eyes (594 ± 40 cells/mm2, n=60, p<0.0001).

Conclusions : Intravitreal ShH10.NT4 results in a reduction in eye pressure and milder anterior segment findings compared to untreated control eyes in the DBA/2J mouse. Increased expression of NT4 is demonstrated in ocular tissues of ShH10.NT4 treated eyes with improved RGC survival compared to ShH10.GFP and untreated control eyes. These findings suggest that Müller glial cell-specific delivery of NT4 may hold promise as a potential therapy for glaucoma by promoting retinal ganglion cell survival.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×